Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China

BackgroundLipid-lowering therapy (LLT) is one of the key strategies for reducing the atherosclerotic cardiovascular disease (ASCVD) burden. However, little is known about the percentage of people in need of different LLT regimens to achieve optimal targets of low-density lipoprotein cholesterol (LDL...

Full description

Bibliographic Details
Main Authors: Lei Bi, Jiayi Yi, Chaoqun Wu, Shuang Hu, Xingyi Zhang, Jiapeng Lu, Jiamin Liu, Haibo Zhang, Yang Yang, Jianlan Cui, Wei Xu, Lijuan Song, Yuanlin Guo, Xi Li, Xin Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
ASCVD risk
LDL-C goals
lipid-lowering therapy
simulation
statins
ezetimibe
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.839571/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.839571/full

Similar Items